Cgmp RE-supply of HPV 16L1/16RG1
Ended Awarded Last action
- Contract number
- 75N91021F00001
- Awardee
-
Kindred Biosciences, Inc. UEI GQEBHPTLG7Y1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $576,173
Award facts
- Contract value 44% obligated
-
- $576,173.48 Current, with exercised options
- $1,321,343.48 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Hillsborough, CA 94010, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$279,101 | |
| Original award | $855,274 |
About this award
Kindred Biosciences, Inc., doing business as Kindred Bio, has been awarded a $1.3 million delivery order against the Prevent Cancer Preclinical Drug Development Program master indefinite-delivery/indefinite-quantity (IDIQ) contract by the National Cancer Institute (NCI), a component of the Department of Health and Human Services' National Institutes of Health (NIH). Under the delivery order, Kindred Bio will provide CGMP re-supply of HPV 16L1/16RG1 to support preclinical development efforts aimed at evaluating potential cancer prevention therapies. The one-year base period of performance runs from February 2021 through February 2022. The contract utilizes a cost-plus-fixed-fee pricing structure and will be performed at Kindred Bio's facility in Burlingame, California. No subcontractors or set-aside designations were identified. The award continues the NCI's work to expedite translational research under the Prevent Cancer program.
Quick answers
Who was awarded contract 75N91021F00001?
75N91021F00001 was awarded to Kindred Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on February 26, 2021.
How much is contract 75N91021F00001 worth?
The government has obligated $576,173 on 75N91021F00001. Its potential value, with all options, is $1,321,343.
Is contract 75N91021F00001 an order under another contract?
Yes. 75N91021F00001 is a delivery order under 75N91019D00027, an indefinite delivery contract, on PREVENT Cancer Preclinical Drug Development Program.
Was contract 75N91021F00001 competed?
The extent of competition for 75N91021F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award